glp-1 winter garden Support – Magnolia Pharmacy Weight & Metabolic Health in

Coverage varies widely

This drug not only reduced total fat mass but also supported the growth of lean body mass

doi:10.1016/j.jacbts.2022.12.011 Collins L, Costello RA

In the key Phase 3 ATTAIN-1 trial published in the New England Journal of Medicine in 2025, once-daily orforglipron 36 mg produced mean body weight reductions of 11.2% at 72 weeks in adults with obesity, with nearly 55% of participants achieving at least 10% weight loss and 36% achieving 15% or more

The clinical evidence base for semaglutide as an active pharmaceutical ingredient applies to the studied FDA-approved formulations, not directly to compounded versions

CagriSema has completed Phase 3 trials and Novo Nordisk is expected to file for FDA approval